Milipitas, CA-based Bigfoot Biomedical Inc. announced on 2 June it closed a $55m series C financing, which was led by Abbott Laboratories Inc. with support from existing investors including Quadrant Capital Advisors, Senvest Capital, Janus Henderson and Cormorant Asset Management and new investors including the Smile Group.
The company said it will use the proceeds from the financing to complete the product development and file for US Food and Drug Administration submission of its insulin delivery system...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?